Literature DB >> 19398885

Retinopathy: an overlooked adverse effect of interferon-beta treatment of multiple sclerosis.

Masayuki Ohira1, Daisuke Ito, Toshihiko Shimizu, Mamoru Shibata, Hisao Ohde, Norihiro Suzuki.   

Abstract

Interferon (IFN), which is an established maintaining therapy for multiple sclerosis (MS), has been reported various adverse effects. This paper describes a case of IFN-associated retinopathy, representing an overlooked adverse effect in MS. A 46-year-old woman with diabetes mellitus was diagnosed with MS and treated with IFNbeta-1b for three years. She displayed sudden defect of the visual field and ocular fundi showed retinal cotton wool spots indicating IFN-retinopathy, which resolved rapidly after IFN was discontinued. To evaluate the prevalence of retinopathy in MS, we performed fundoscopic examination on twenty MS patients treated with IFNbeta-1b in our hospital. However, none of the patients displayed retinopathy. Only four other cases of IFN- retinopathy in MS have been reported in the literature. Therefore, IFN-retinopathy may be uncommon in MS, but neurologist should be mindful of this adverse effect and regularly check the fundus, particularly in patients with possible risk factor, diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398885     DOI: 10.2302/kjm.58.54

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  6 in total

1.  Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.

Authors:  Julia Button; Omar Al-Louzi; Andrew Lang; Pavan Bhargava; Scott D Newsome; Teresa Frohman; Laura J Balcer; Elliot M Frohman; Jerry Prince; Peter A Calabresi; Shiv Saidha
Journal:  Neurology       Date:  2017-01-11       Impact factor: 9.910

Review 2.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 3.  Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature.

Authors:  Lorenzo Gaetani; Paola S Menduno; Francesco Cometa; Maria Di Gregorio; Paola Sarchielli; Carlo Cagini; Paolo Calabresi; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2015-08-21       Impact factor: 4.849

4.  [Combined retinal artery and vein occlusions associated with interferon beta therapy].

Authors:  T Jenisch; T Dietrich-Ntoukas; A B Renner; H Helbig; M A Gamulescu
Journal:  Ophthalmologe       Date:  2012-01       Impact factor: 1.059

Review 5.  Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Juliana Reyes-Guanes; Estefanía Zapata-Bravo; Laura Mora-Muñoz; Juan Antonio Reyes-Hurtado; Luis Octavio Tierradentro-García; William Rojas-Carabali; Marcela Gómez-Suarez; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-10-28

6.  Interferons and their potential in the treatment of ocular inflammation.

Authors:  Friederike Mackensen; Regina Max; Matthias D Becker
Journal:  Clin Ophthalmol       Date:  2009-10-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.